Biomarker driven, agentic AI heart failure system of care
that is scalable to all patients in all care settings
to materially improve patient outcomes.
Our differentiation is in capturing an accurate (absolute and direct) biomarker of worsening heart failure with a low cost, simple-to-use, non-invasive device. This approach is highly scalable across diverse healthcare settings and patient populations.
The lung fluid biomarker directly supports Guideline Directed Medical Therapy (GDMT) optimization and easily integrates into existing clinician workflows.
Lifewave’s CardioConnect™ system-of-care engages and empowers patients and their clinicians to proactively manage acute and chronic heart failure in home and remote settings.
Our AI-powered platform automates and distributes clinician workflows to optimize time and addresses clinician burnout.
The LifeWave heart failure solution will be evidence-based and supportive of value-based care through current economic frameworks and our SaaS business model.
Investigational Device. Limited United States Law to Investigational Use.
CardioConnect™ Platform Solution
- Agentic AI platform supporting Personalized Care & Supervised Self-Management
- Worsening Heart Failure Biomarker with Lung Fluid Measurement
- Non-Invasive Direct and Absolute Measure
- 15 sec. Capture over Clothing - BMI Agnostic
- Actionable and Algorithmic Therapeutic Guidance
- Supports Fluid Stabilization and GDMT Management
Harnessing Agentic AI to Improve Heart Failure Outcomes
LifeWave is building a system of care to improve the clinical outcomes of heart failure patients. Empowered by agentic AI, the system enables personalized care and patient self-management that stands to avert hospitalizations in any care setting and increase the number of quality days at home for patients, especially when cardiology care may not be available.
Among heart failure patients, steady yet asymptomatic, episodic increases in lung fluid are the number-one factor driving ER visits and hospitalizations. The patient-facing agent assembles physiologic monitoring data and connects with patient EHR records and clinician workflow to inform therapy that will stabilize fluids and optimize GSMT. The agent also facilitates clinician communications, appointment scheduling, diet and physical activity recommendations, medication management, and coordination with the patient’s caregiver agent. Following FDA approval of CardioConnect, LifeWave’s proprietary device for lung fluid measurement, the device will be integrated into the agent platform to provide an early-detection, “ground-truth” biomarker of worsening heart failure–simplifying patient self-management and clinician management.
Medical Radar Technology
LifeWave has developed a broad base of intellectual property (nine issued USPTO patents) and expertise in medical radar which uses low-power, Ultra-Wideband (UWB) radio frequency (RF) energy for physiologic assessment. The LifeWave technology meets Federal Communications Commission regulations governing human RF exposure and UWB spectrum for a portable medical device.
Leadership Team
LifeWave Biomedical is led by a team of proven executives across cardiology, digital health, operations, and medical technology. With deep expertise spanning patient care, product innovation, commercialization, and large-scale adoption, the team is united by a mission to transform heart failure management worldwide. A team of proven leaders uniting clinical, operational, and technology expertise to transform heart failure care.
Clinical
Advisors
LifeWave has engaged clinical heart failure leaders to inform our product strategy and clinical outcome studies.
Investors
LifeWave is currently raising a Series B Financing.
Health System Relationships
LifeWave is collaborating with leading value-based care healthcare systems.